Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600120442) titled 'Iparomlimab and Tuvonralimab Combined with Bevacizumab and Chemotherapy for the Treatment of Recurrent Ovarian Clear Cell Carcinoma: A Single-Center, Single-Arm Clinical Study' on March 13.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Fudan University Shanghai Cancer Center
Condition:
platinum-sesitive recurrence ovarian clear cell cancer
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-03-31
Target Sample Size: Experimental group:37;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=302164
Di...